Triple Receptor Agonist (GLP-1, GIP & Glucagon) | Fat Loss, Appetite Suppression & Metabolic Enhancement | For Research Use Only

Retatrutide is a cutting-edge investigational peptide that acts as a triple agonist of the GLP-1, GIP, and glucagon receptors. This triple mechanism has demonstrated unprecedented weight loss, improved glycaemic control, and enhanced energy expenditure in early-phase research studies. It is currently one of the most promising agents under investigation for obesity, type 2 diabetes, and metabolic dysfunction.

With a long half-life and superior fat-burning properties, Retatrutide is paving the way for next-generation peptide therapeutics.

🔍 Key Features

• Triple Receptor Activation: GLP-1, GIP & Glucagon

• Potent Appetite Suppression & Satiety Induction

• Accelerates Fat Burning & Promotes Lean Mass Retention

• Improves Insulin Sensitivity & Glucose Regulation

• Superior to Semaglutide & Tirzepatide in Preclinical Trials

• Ideal for Advanced Weight Management & Diabetic Research Models

⚙️ Compound Details

• Compound Name: Retatrutide

• CAS Number: 2381089-83-2

• Molecular Formula: C₂₀₉H₃₂₉N₅₅O₆₆

• Molecular Weight: ~4717.35 g/mol

• Purity: ≥ 98% (HPLC Verified)

• Form: Lyophilised powder

• Unit Size: 50mg per vial

🧊 Storage & Handling

• Storage (lyophilised): Store at –20°C, protected from light and moisture

• Reconstitution: Reconstitute with sterile bacteriostatic water (1–2ml recommended)

• Post-Reconstitution: Store at 2–8°C and use within 10–14 days

• Avoid: Heat exposure, light, and repeated freeze-thaw cycles

⚠️ For Research Use Only

Retatrutide – 50mg is intended strictly for scientific, non-human research purposes. It is not approved for human use, medical treatment, or diagnostic procedures.